ad image

Company Info

Eisai

Eisai

Drug Discovery & Development

Overview

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.
Eisai
Contributions
14 Contributions1 / 1
Eisai
Clinical Treatment

Eisai Completes Submission to US FDA for LEQEMBI Application for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai

PR-10-24-NI-70Nov 01, 2024
Eisai
Insomnia

New Insomnia Treatment Approved by the FDA for Adults

Eisai

PR-M01-20-NI-002Jan 02, 2020
Eisai
Appointment

Eisai Inc. Deepens Its Commitment to Alzheimer's Disease with Key Executive Appointments

Eisai

PR-M05-19-NI-015May 06, 2019
Eisai
Agreement

Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.

Eisai

PR-M02-19-NI-048Feb 21, 2019
Eisai
Phase III

Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study: Advances in Sleep and Circadian Science

Eisai

PR-M02-19-NI-010Feb 06, 2019
Eisai
Alzheimer's Disease

First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials

Eisai

PR-M12-18-NI-037Dec 12, 2018
Eisai
Epilepsy

New Analyses Evaluate Long-Term Convulsive Seizure Freedom Rates With Use Of Adjunctive FYCOMPA® (perampanel) CIII In Adult Patients Presented at Annual Meeting of the AES

Eisai

PR-M12-18-NI-015Dec 05, 2018
Eisai
Pediatric

Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures

Eisai

PR-M10-18-NI-022-3589Oct 05, 2018
Eisai
FDA Approval

Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

Eisai

PR-M09-18-NI-070Sep 24, 2018
Eisai
Study Results

Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease

Eisai

PR-M07-18-NI-103Jul 31, 2018
Eisai
Clinical Data

Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®

Eisai

PR-M07-18-NI-056Jul 18, 2018
Eisai
Drug Discovery

Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts

Eisai

PR-M06-18-NI-044Jun 13, 2018
Eisai
Strategic Collaboration

Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)

Eisai

PR-M03-18-NI-046Mar 13, 2018
Eisai
Breakthrough Therapy

Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy 

Eisai

PR-M01-18-NI-032Jan 12, 2018
1 / 1
0 Contributors1 / 0

No authors found

1 / 0